Melanoma Institute part of $14m melanoma project grant
25 March 2015
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
The research, funded as part of the National Health and Medical Research Council (NHMRC) Program scheme, will commence in 2016 and will be administered through Macquarie University in Sydney. The team’s investigators are largely based at the University of Sydney, as well as the Centenary Institute, the Westmead Millennium Institute for Medical Research, and the QIMR Berghofer Medical Research Institute.
All investigators are part of MIA, the world’s largest cancer centre dedicated to research and treatment of melanoma, and have been linked as a NHMRC Program since 2006. Treating 1900 new melanoma patients annually, the MIA’s repository of clinical research data and melanoma biospecimens is the largest in the world.
Lead researcher Professor Rick Kefford from MIA and Macquarie University said the project had real prospects of accelerating prevention and early detection of melanoma.
“In this era of rapid change the program could make realistic progress towards a cure of metastatic disease,” Professor Kefford said.
MIA tumour samples and data from people receiving targeted and immune treatments for melanoma are driving these promising advances. The Program has also recruited thousands of people from the community, and families with a strong history of melanoma, to lead discovery of melanoma risk genes.
“In the last few years our program has helped drive large-scale genomic analysis of melanoma, and this will continue to be a cornerstone of our research,” says Professor Graham Mann of MIA, Westmead Millennium Institute and the University of Sydney. “These approaches have already been highly successful, and we have great hopes for better prevention, detection and treatment of melanoma in the future,” he said.
Highlights in melanoma research from ESMO
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers stopping melanoma in its tracks
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
Virus-antibody combo shows promise for treating advanced melanoma
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It's time to outlaw sunburn on reality TV shows - enough is enough
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Identifying markers for optimal response
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
Global Melanoma Research Report - July
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
A day in the life of... Sarah Lane
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Differentiating moles from melanoma
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
Introducing SunSense Sunscreen
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
60 Minutes' MIA Patient Feature Program
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Training our future melanoma experts
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Update from ASCO 2017
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
Diagnosing melanoma of the mouth
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New practice-changing research will reduce the need for major surgery in many melanoma patients
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
MIA researchers to share new findings at world's largest cancer conference
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 wraps up!
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Melanoma March 2017 helping kick start the Big Data for Melanoma national Research Project!
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
Whole genome sequencing finds unexpected genomic landscape in melanoma
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.